Monday 25 October 2021
- Advertisement -
HomePoliticsWorldEuropean countries suspend use of AstraZeneca vaccine

European countries suspend use of AstraZeneca vaccine

European nations have suspended the use of AstraZeneca vaccines from a batch that was sent to 17 countries and consisted of one million jabs

|

Denmark, Norway and Iceland on 11 March temporarily the use of AstraZeneca’s Covid-19 vaccine over concerns about patients developing post-jab blood clots, as the manufacturer and European medicines watchdog insisted the vaccine was safe.

Denmark was the first among European nations to announce the suspension, “following reports of serious cases of blood clots” among people who had received the vaccine, the country’s Health Authority said in a statement. It insisted that the move was precautionary, and that “it has not been determined, at the time being, that there is a link between the vaccine and the blood clots”.

As of 9 March, 22 cases of blood clots had been reported among more than three million people vaccinated in the European Economic Area, the European Medicines Agency (EMA) said.

Austria announced on 8 March that it had the use of a batch of AstraZeneca vaccines after a 49-year-old nurse died of “severe blood coagulation problems” days after receiving an anti-Covid shot.

Four other European countries — Estonia, Latvia, Lithuania and Luxemburg — have the use of vaccines from this batch, which was sent to 17 European countries and consisted of one million shots.

Denmark the use of all of its AstraZeneca supply, as did Iceland and Norway in subsequent announcements on 11 March citing similar concerns.

On 10 March, the EMA said that a preliminary probe had shown that the batch of AstraZeneca vaccines used in Austria was likely not to blame for the nurse’s death.

“This is a super-cautious approach based on some isolated reports in Europe,” said Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene and Tropical Medicine. “The risk and benefit balance is still very much in favour of the vaccine,” he said.

AstraZeneca, an Anglo-Swedish company that developed the vaccine with Oxford University, defended the of its product. “The safety of the vaccine has been extensively studied in phase III clinical trials and peer-reviewed data confirms the vaccine has been generally well-tolerated,” a spokesman for the group told AFP.

Britain, whose widely-praised vaccine rollout has been largely underpinned by the AstraZeneca jab, also defended it as “both safe and effective”.

The Danish suspension, which will be reviewed after two weeks, is expected to slow down the country’s vaccination campaign.

Denmark now expects to have its entire adult population vaccinated by mid-August instead of early July, the health authority said. “We are of course saddened by this news,” said Prime Minister Mette Frederiksen.

Frederiksen, who has pushed for the production of more vaccines and has formed a controversial alliance with Austria and Israel to do so, defended the Danish health authorities’ decision. “There is always a risk associated with vaccines,” she said.

“Things have gone well in Denmark, but there are some risks linked to the AstraZeneca vaccine that need to be examined more closely. That seems to me to be the right way to proceed.”

Danish Health Authority director Soren Brostrom stressed that “we have not terminated the use of the AstraZeneca vaccine, we are just pausing its use”.

“There is broad documentation proving that the vaccine is both safe and efficient,” Brostrom said, “but both we and the Danish Medicines Agency must act on information about possible serious side effects, both in Denmark and in other European countries.”

Denmark said one person had died after receiving the vaccine. The EMA has launched an investigation into that death.

In the Scandinavian country of 5.8 million, around 25% of those who have received a first dose were given the AstraZeneca jab. In total, 3.8% of the population has received two doses of vaccine and 13.4% at least one dose.

Sirf News needs to recruit journalists in large numbers to increase the volume of its reports and articles to at least 100 a day, which will make us mainstream, which is necessary to challenge the anti-India discourse by established media houses. Besides there are monthly liabilities like the subscription fees of news agencies, the cost of a dedicated server, office maintenance, marketing expenses, etc. Donation is our only source of income. Please serve the cause of the nation by donating generously.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

- Advertisment -

Now

Columns

[prisna-google-website-translator]